FGFilippo Greco

Filippo Greco

*This is an algorithmically generated author record based on publicly available information.

Filippo Greco has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Bonetti

    Department of Oncology, Mater Salutis Hospital, Legnago, Italy

    2 shared publications
  • Domenica Lorusso

    Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy

    2 shared publications
  • Jacopo Giuliani

    Department of Clinical Oncology, Section of Medical Oncology, AULSS 9 Scaligera, 37045 Legnago, Italy

    2 shared publications
  • Sandro Pignata

    Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy

    2 shared publications
  • A. Passarelli

    Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy

    1 shared publication
  • A. Spina

    Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy

    1 shared publication

Latest Publications

  • Open Access

    Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

    by M. Bartoletti, A. Passarelli, A. Fagotti, C. Andreetta, S. Tamberi, D. Lorusso, C. Pisano, D. Califano, A. Spina, C. De Angelis, et al.


  • Open Access

    Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study

    by Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, Francesca Sofia Di Lisa, Antonio Astone, Claudia Cutigni, Jennifer Foglietta, Martina Nunzi, Rosalinda Rossi, Mauro Minelli, et al.

    Background/Objectives: HER2-positive breast cancer (HER2+BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been established as the standard of care in the adjuvant setting for HER2+BC patients who do not obtain pCR. The ATD study aimed to evaluate the real-world tolerability of T-DM1 in this setting. The secondary objective was to assess the effectiveness. Methods: This was a multicenter, retrospective study across 24 Italian oncology centers, including 410 patients with HER2+BC treated with adjuvant T-DM1 following a lack of pCR after NAT. Patient characteristics, NAT regimens, and surgical outcomes were recorded. Tolerability was assessed by documenting adverse events (AEs) according to the CTCAE (v5.0). Preliminary effectiveness was evaluated in terms of relapse-free survival (RFS) and overall survival (OS). Results: Overall, 228 patients (55.6%) experienced at least one AE related to T-DM1, with 4.9% experiencing grade 3 or higher AEs. The most common AEs were hepatotoxicity (18.5%) and thrombocytopenia (17.6%). T-DM1 was discontinued in 10.0% of patients due to toxicity. After a median follow-up of 25 months, 31 relapse events (7.6%) and 22 deaths (5.4%) were reported. The preliminary incidence of RFS and OS events was similar between patients who completed the T-DM1 course and those who discontinued it early. Conclusions: T-DM1 demonstrated a manageable safety profile, and the adverse events were consistent with those reported in randomized trials. The data are not yet sufficient to allow for a formal analysis of RFS and OS, and long-term follow-up is required.


  • Open Access

    Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21)

    by Grazia Artioli, Gaia Giannone, Giorgio Valabrega, Furio Maggiorotto, Sofia Genta, Sandro Pignata, Domenica Lorusso, Gennaro Cormio, Simona Scalone, Maria Ornella Nicoletto, et al.


  • Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report

    by Pietro Parcesepe, Guido Giordano, Caterina Zanella, Jacopo Giuliani, Filippo Greco, Andrea Bonetti, Massimo Pancione, Erminia Manfrin, Enrico Molinari, Tiziana Pia Latiano, et al.


  • Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer

    by Paolo Piacentini, Filippo Greco, Anna Mercanti, Anna Rita Trolese, Emilia Durante, Giacomo Moratello, Michele Tognetto, Lara Furini, Jacopo Giuliani, Andrea Bonetti

    More than 50% of patients with advanced non-small cell lung cancer are diagnosed in the elderly. Few prospective clinical data with cisplatin-based chemotherapy are available, and some authors have suggested that a non-platinum single agent should be the preferred form of cure in these patients. The aim of the study was to evaluate the efficacy and safety of first-line chemotherapy based on platinums (carboplatin or cisplatin) plus a third generation compound (vinorelbine or gemcitabine) in elderly patients with advanced non-small cell lung cancer in daily clinical practice. A retrospective analysis of consecutive elderly (≥70 years of age) patients with advanced non-small cell lung cancer treated at our Medical Oncology Unit from February 2005 to September 2011 was performed. A total of 249 cycles of chemotherapy was administered to 62 patients (median age, 72 years; range, 70-81) presenting a median Charlson comorbidity index of 1 and a good ECOG PS (0-1, 52 patients; 2, 10 patients). The median number of cycles/patient was 4, and all 62 patients received a platinum-based doublet as first-line chemotherapy: 57 with carboplatin (92%) and 5 with cisplatin (8%). As best response to the treatment, 19 (31%) partial responses and 20 (32%) stable diseases were observed. Median overall survival was 9.8 months. Toxicity was mild; grade III-IV neutropenia was the most frequently observed side effect in 19 administered cycles (8%). Advanced non-small cell lung cancer in elderly patients can be safely treated with a platinum-based doublet. Observed toxicity is manageable, and overall survival is in keeping with data from the literature.